Trial Profile
Efficacy and safety in adequate regimen of anti-vascular endothelial growth factor (VEGF) therapy for patients with diabetic macular edema
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 27 May 2016
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Diabetic macular oedema
- Focus Therapeutic Use
- 27 May 2016 New trial record